Подписаться
Bulent Ozpolat
Bulent Ozpolat
Houston methodist resercah institute
Подтвержден адрес электронной почты в домене houstonmethodist.org
Название
Процитировано
Процитировано
Год
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
13246*2021
Paraneoplastic thrombocytosis in ovarian cancer
RL Stone, AM Nick, IA McNeish, F Balkwill, HD Han, J Bottsford-Miller, ...
New England Journal of Medicine 366 (7), 610-618, 2012
8552012
Preclinical and clinical development of siRNA-based therapeutics
G Ozcan, B Ozpolat, RL Coleman, AK Sood, G Lopez-Berestein
Advanced drug delivery reviews 87, 108-119, 2015
5262015
Targeting the pro-death and pro-survival functions of autophagy as novel therapeutic strategies in cancer
K Dalby, I Tekedereli, G Lopez-Berestein, B Ozpolat
Autophagy 6 (3), 322-329, 2010
5122010
Liposomal siRNA nanocarriers for cancer therapy
B Ozpolat, AK Sood, G Lopez-Berestein
Advanced drug delivery reviews 66, 110-116, 2014
4642014
Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells
U Akar, A Chaves-Reyez, M Barria, A Tari, A Sanguino, Y Kondo, ...
Autophagy 4 (5), 669-679, 2008
3232008
Nanomedicine based approaches for the delivery of siRNA in cancer
B Ozpolat, AK Sood, G Lopez‐Berestein
Journal of internal medicine 267 (1), 44-53, 2010
2802010
Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer
N Hasima, B Ozpolat
Cell death & disease 5 (11), e1509-e1509, 2014
2702014
Nanotechnology in cancer therapy
B Aslan, B Ozpolat, AK Sood, G Lopez-Berestein
Journal of drug targeting 21 (10), 904-913, 2013
2002013
Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer
P Kanlikilicer, R Bayraktar, M Denizli, MH Rashed, C Ivan, B Aslan, ...
EBioMedicine 38, 100-112, 2018
1812018
RNAi-based therapeutics and tumor targeted delivery in cancer
G Kara, GA Calin, B Ozpolat
Advanced drug delivery reviews 182, 114113, 2022
1692022
Tissue transglutaminase inhibits autophagy in pancreatic cancer cells
U Akar, B Ozpolat, K Mehta, J Fok, Y Kondo, G Lopez-Berestein
Molecular Cancer Research 5 (3), 241-249, 2007
1542007
Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia
MN Harris, B Ozpolat, F Abdi, S Gu, A Legler, KG Mawuenyega, ...
Blood 104 (5), 1314-1323, 2004
1422004
Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer
I Tekedereli, SN Alpay, CDJ Tavares, ZE Cobanoglu, TS Kaoud, I Sahin, ...
PloS one 7 (7), e41171, 2012
1402012
Targeting autophagy in cancer management–strategies and developments
B Ozpolat, DM Benbrook
Cancer management and research, 291-299, 2015
1342015
Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells
P Kanlikilicer, MH Rashed, R Bayraktar, R Mitra, C Ivan, B Aslan, X Zhang, ...
Cancer research 76 (24), 7194-7207, 2016
1292016
Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in …
I Tekedereli, SN Alpay, U Akar, E Yuca, C Ayugo-Rodriguez, HD Han, ...
Molecular Therapy-Nucleic Acids 2, 2013
1222013
MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase
R Bayraktar, M Pichler, P Kanlikilicer, C Ivan, E Bayraktar, N Kahraman, ...
Oncotarget 8 (7), 11641, 2017
1192017
Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers
B Ozpolat, G Lopez-Berestein, P Adamson, CJ Fu, AH Williams
J Pharm Pharm Sci 6 (2), 292-301, 2003
1182003
Pancreatic cancer stem cells and therapeutic approaches
G Ercan, A Karlitepe, B Ozpolat
Anticancer research 37 (6), 2761-2775, 2017
1162017
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20